Focal Point Lab 360 — Full Financial Presentation
Executive summary
Focal Point Lab 360 is presented as a lab-enabled healthcare operations platform: testing workflow, secure client portal, AI-assisted revenue-cycle management, logistics coordination, and facility/agent performance reporting. The financial model is organized for investor review: first the offering and valuation framework, then launch budget, revenue projection, operating expense model, and monthly profit view. The operating model uses the current test-menu and volume assumptions, with test volume increasing by 10% each quarter through Year 2.
| Summary item | Amount |
|---|
| Launch budget | $1,390,000 |
| Year 1 gross collections | $4,975,573.88 |
| Year 1 operating expense estimate | $3,609,154.52 |
| Year 1 net profit before launch budget recovery | $1,366,419.36 |
| Year 1 net after launch budget | ($23,580.64) |
| Year 2 gross collections | $7,284,737.72 |
| Year 2 operating expense estimate | $4,503,871.80 |
| Year 2 net profit before launch budget recovery | $2,780,865.91 |
| 24-month net after launch budget | $2,757,285.27 |
1. Offering, valuation, and Round 1 owner-share framework
This section frames Focal Point Lab 360 as a lab-enabled healthcare operations platform: laboratory services, secure client workflow, AI-assisted billing and revenue-cycle management, facility reporting, supply logistics, courier/mobile phlebotomy coordination, and agent/referral performance tracking. The investment case is that the business is not only a lab launch; it is an operating system for profitable testing volume.
Investment thesis
- Problem: recovery-focused lab workflows often split requisitions, results, payer status, logistics, collections, and referral attribution across disconnected tools.
- Solution: Focal Point Lab 360 connects client workflow, lab operations, AI-assisted billing, and performance reporting in one secure operating layer.
- Revenue protection: claim readiness, prior authorization flags, denial prevention, A/R aging, and payment posting visibility are built into the workflow instead of handled after the fact.
- Scalability: the model can expand by facility, payer, test menu, region, and agent network while preserving centralized reporting.
- Valuation logic: the preferred framing is hybrid healthcare operations + software-enabled revenue cycle, with a discounted owner round for early risk.
Valuation position
| Case | Basis | Implied enterprise value | Use in discussion |
|---|
| Conservative lab-only case | ~5x Year 2 projected net profit / EBITDA proxy | $13.9M | Downside anchor if valued as services only |
| Hybrid lab + AI billing platform | ~7x–9x Year 2 projected net profit / EBITDA proxy | $19.5M–$25.0M | Primary valuation logic |
| Strategic AI healthcare platform upside | ~10x–12x Year 2 projected net profit / EBITDA proxy | $27.8M–$33.4M | Upside case after proof of traction |
| Recommended discussion range | Platform value with execution discount | $22M–$28M | Investor / partner presentation range |
Round 1 owner / strategic partner round
The Round 1 owner round is structured as an early strategic owner round with a discount to the $22M–$28M platform valuation discussion range. The purpose is to fund launch, software buildout, revenue-cycle infrastructure, compliance, and working capital while preserving founder control and giving early aligned capital a clear ownership entry point.
| Headline term | Proposed value | Investor meaning |
|---|
| Target raise | $1,750,000 | Funds launch budget plus software, compliance, and working capital buffer. |
| Discounted Round 1 pre-money | $20,000,000 | Below the $22M–$28M platform discussion range to reward early execution risk. |
| Owner-round price | $2.00/share | Simple pricing from a 10,000,000 pre-round share base. |
| Ownership at full raise | ~8.05% | Based on 875,000 new shares before option pool, advisor equity, or later financing. |
| Term | Proposed structure | Rationale |
|---|
| Round type | Round 1 Owner / Strategic Partner Round | Early insiders, operators, and aligned strategic capital |
| Security | Common or preferred equity, subject to attorney/tax review | Final structure should be set in corporate and securities documents |
| Pre-money valuation | $20,000,000 | Discounted from target platform valuation to reward early risk |
| Pre-round share base | 10,000,000 shares | Clean capitalization assumption for pricing math |
| Round 1 price per share | $2.00 per share | $20,000,000 pre-money ÷ 10,000,000 pre-round shares |
| Target raise | $1,750,000 | Covers $1.39M launch budget plus working capital/compliance/software buffer |
| New shares issued at target raise | 875,000 shares | $1,750,000 ÷ $2.00/share |
| Post-money valuation | $21,750,000 | $20,000,000 pre-money + $1,750,000 new capital |
| Post-round total shares | 10,875,000 shares | 10,000,000 existing + 875,000 new shares |
| Investor ownership at full target raise | ~8.05% | 875,000 ÷ 10,875,000 post-round shares |
| Founder/existing ownership after full target raise | ~91.95% | Before any option pool, advisor equity, or later financing |
Round 1 investment examples at $2.00/share
| Investment | Shares purchased | Approx. post-round ownership if full $1.75M is raised |
|---|
| $25,000 | 12,500 shares | 0.11% |
| $50,000 | 25,000 shares | 0.23% |
| $100,000 | 50,000 shares | 0.46% |
| $250,000 | 125,000 shares | 1.15% |
| $500,000 | 250,000 shares | 2.30% |
Use of proceeds
| Use | Estimated allocation | Purpose |
|---|
| Lab launch budget | $1,390,000 | Equipment, licensing, validation, LIMS, facility, compliance, startup operating requirements |
| AI billing / revenue-cycle system | $150,000 | Claim monitoring, eligibility, prior auth, denial/appeal workflows, reporting, and payer logic |
| Portal / SIMS / workflow software | $100,000 | Client portal, requisitions, results, supplies, courier/mobile phlebotomy, facility reporting |
| Compliance / legal / securities / corporate | $60,000 | Healthcare compliance, securities documents, contracts, policies, data/privacy controls |
| Working capital reserve | $50,000 | Launch cushion and early operating buffer |
| Total target raise | $1,750,000 | Round 1 owner / strategic partner funding target |
Alternative higher-valuation price reference
If the round is priced at the $25M platform valuation anchor instead of the discounted $20M owner-round value, the price would be $2.50/share on the same 10,000,000 pre-round share base. At a $1.75M raise, that would issue 700,000 shares and represent approximately 6.54% post-round ownership. The $2.00/share owner-round structure is cleaner and more attractive for aligned early capital.
Securities and legal note
This is a planning model only. Not an offer to sell securities. Any stock sale, private placement, subscription agreement, SAFE/convertible note, preferred equity round, or ownership issuance must be reviewed by securities counsel and tax counsel before being presented or offered to investors. Final documents should define issuer entity, authorized shares, founder shares, vesting, investor rights, transfer restrictions, accredited investor requirements, Form D/state blue-sky filings if applicable, risk factors, use of proceeds, and whether the offering is conducted under Rule 506(b), Rule 506(c), Regulation CF, Regulation A, or another exemption.
2. Launch budget
| # | Category | Detail | Estimated cost |
|---|
| 1 | Facility / basic lab buildout | Facility buildout, lab benches, utilities, specimen receiving, secure storage, waste setup | $75,000 |
| 2 | Licensing / Compliance | Two separate CLIA license/certificate setups, one COLA accreditation, SOPs, policies, proficiency setup | $35,000 |
| 3 | General lab equipment | Biosafety cabinet, centrifuges, refrigerators/freezers, pipettes, balances, workstations, lab furniture | $50,000 |
| 4 | Toxicology screening equipment | Presumptive tox analyzer/lease setup, calibration materials, startup validation | $25,000 |
| 5 | Definitive confirmation equipment / lease setup | LC-MS/MS or equivalent confirmation platform lease/setup, installation, validation | $250,000 |
| 6 | Molecular / PCR equipment | PGx and UTI PCR equipment, extraction system, qPCR platform, molecular workspace setup | $125,000 |
| 7 | Initial supplies & reagents | Collection supplies, controls, calibrators, reagents, extraction kits, PCR consumables, tox supplies, PPE | $125,000 |
| 8 | IT / hardware / security | Computers, barcode printers/scanners, secure network, backup, cybersecurity, workstations | $20,000 |
| 9 | LIMS software integration fee | LIMS system integration we provide/build | $25,000 |
| 10 | AI smart billing integration fee | AI billing workflow, payer logic, claim-support automation, dashboard/reconciliation setup | $25,000 |
| 11 | Validation / training / go-live support | Method validation, staff training, workflow testing, LIMS/LIS testing, billing workflow dry runs | $25,000 |
| 12 | Initial staff payroll reserve | Approximately 90-day payroll reserve | $170,000 |
| 13 | Professional fees | Legal, accounting, compliance consultant, billing consultant, credentialing support | $25,000 |
| 14 | Insurance / risk management | General liability, professional liability, cyber, workers comp, equipment coverage | $15,000 |
| 15 | Working capital reserve | Cash reserve for AR lag, denials, payroll, vendor deposits, payer delays | $250,000 |
| 16 | Contingency reserve | Contingency cushion for overruns | $150,000 |
| Total launch budget | | $1,390,000 |
Licensing / compliance detail
| Item | Estimated cost |
|---|
| CLIA license / certificate setup #1 | $7,500 |
| CLIA license / certificate setup #2 | $7,500 |
| COLA accreditation setup | $10,000 |
| SOPs, compliance binder, policies, proficiency testing setup, consulting support | $10,000 |
| Total Licensing / Compliance | $35,000 |
3. Revenue projection — 24 months with 10% quarterly volume growth
Test menu, codes billed per test, and baseline monthly volume
| Test category | Code billed per test | Monthly baseline volume | Benchmark rate used | Payer-weighted allowed per test | Baseline gross allowed / month |
|---|
| Tox screen / presumptive | 80307 | 1,000 | CMS CLFS 80307 = $62.14 | $61.21 | $61,207.90 |
| Full confirmation / definitive | G0483 | 1,000 | CMS CLFS G0483 = $246.92 | $243.22 | $243,216.20 |
| PGx pharmacogenomics | 81418 | 100 | CMS CLFS 81418 = $917.08 | $903.32 | $90,332.38 |
| UTI PCR pathogen panel | 0504U | 100 | CMS CLFS 0504U = $416.78 | $410.53 | $41,052.83 |
| Total | | 2,200 | | | $435,809.31 |
Payer mix reimbursement breakdown
Commercial out-of-network allowables vary by payer, plan, state, patient benefits, medical necessity, and appeal success. This model uses the public CMS CLFS rate as the benchmark and applies the payer-weighted out-of-network assumptions below.
| Major payer bucket | Assumed mix | Modeled OON payable vs CMS | Tox screen 80307 | Full confirmation G0483 | PGx 81418 | UTI PCR 0504U |
|---|
| UnitedHealthcare | 20% | 85% | $52.82 | $209.88 | $779.52 | $354.26 |
| Aetna | 15% | 95% | $59.03 | $234.57 | $871.23 | $395.94 |
| Cigna | 15% | 100% | $62.14 | $246.92 | $917.08 | $416.78 |
| BCBS / Blue Plans | 25% | 110% | $68.35 | $271.61 | $1,008.79 | $458.46 |
| Anthem / Elevance | 15% | 105% | $65.25 | $259.27 | $962.93 | $437.62 |
| Humana / Other | 10% | 90% | $55.93 | $222.23 | $825.37 | $375.10 |
| Weighted average | 100% | 98.5% | $61.21 | $243.22 | $903.32 | $410.53 |
Quarterly test volume ramp
| Quarter | Growth applied | Tox 80307 / mo | Confirmation G0483 / mo | PGx 81418 / mo | UTI PCR 0504U / mo | Total tests / mo |
|---|
| Y1 Q1 | Baseline | 1,000 | 1,000 | 100 | 100 | 2,200 |
| Y1 Q2 | +10% over prior quarter | 1,100 | 1,100 | 110 | 110 | 2,420 |
| Y1 Q3 | +10% over prior quarter | 1,210 | 1,210 | 121 | 121 | 2,662 |
| Y1 Q4 | +10% over prior quarter | 1,331 | 1,331 | 133.1 | 133.1 | 2,928.2 |
| Y2 Q1 | +10% over prior quarter | 1,464.1 | 1,464.1 | 146.4 | 146.4 | 3,221.0 |
| Y2 Q2 | +10% over prior quarter | 1,610.5 | 1,610.5 | 161.1 | 161.1 | 3,543.1 |
| Y2 Q3 | +10% over prior quarter | 1,771.6 | 1,771.6 | 177.2 | 177.2 | 3,897.4 |
| Y2 Q4 | +10% over prior quarter | 1,948.7 | 1,948.7 | 194.9 | 194.9 | 4,287.2 |
Revenue totals by scenario
| Period | Scenario | Collection rate | Test volume | Gross allowed value | Gross collections | Billing/software expense | Net to client |
|---|
| Year 1 | Conservative | 70% | 30,630.6 | $6,067,773.02 | $4,247,441.12 | $450,473.88 | $3,796,967.24 |
| Year 1 | Target AI model | 82% | 30,630.6 | $6,067,773.02 | $4,975,573.88 | $501,443.17 | $4,474,130.71 |
| Year 1 | Upside | 90% | 30,630.6 | $6,067,773.02 | $5,460,995.72 | $535,422.70 | $4,925,573.02 |
| Year 2 | Conservative | 70% | 44,846.3 | $8,883,826.48 | $6,218,678.54 | $659,538.80 | $5,559,139.73 |
| Year 2 | Target AI model | 82% | 44,846.3 | $8,883,826.48 | $7,284,737.72 | $734,162.95 | $6,550,574.77 |
| Year 2 | Upside | 90% | 44,846.3 | $8,883,826.48 | $7,995,443.83 | $783,912.38 | $7,211,531.46 |
| 24 months | Conservative | 70% | 75,476.9 | $14,951,599.51 | $10,466,119.65 | $1,110,012.68 | $9,356,106.97 |
| 24 months | Target AI model | 82% | 75,476.9 | $14,951,599.51 | $12,260,311.60 | $1,235,606.12 | $11,024,705.48 |
| 24 months | Upside | 90% | 75,476.9 | $14,951,599.51 | $13,456,439.56 | $1,319,335.08 | $12,137,104.48 |
4. Monthly operating expense model
Staff payroll
| Role | Annual salary assumption | Monthly cost |
|---|
| Lab Director / Medical Director, contracted or part-time | $75,000 | $6,250.00 |
| Clinical Lab Scientist / Medical Lab Scientist, 2 FTE | $140,000 | $11,666.67 |
| Molecular Technologist / PCR Specialist | $75,000 | $6,250.00 |
| Lab Technicians / Accessioning, reduced coverage | $45,000 | $3,750.00 |
| Billing / Revenue Cycle Specialist | $60,000 | $5,000.00 |
| Lab Operations Manager | $90,000 | $7,500.00 |
| Admin / Client Services | $50,000 | $4,166.67 |
| Base payroll | $535,000 | $44,583.33 |
| Payroll taxes / benefits burden @ 18% | $96,300 | $8,025.00 |
| Total staff cost | $631,300 | $52,608.33 |
Monthly operating expense summary by quarter
| Expense group | Y1 Q1 | Y1 Q2 | Y1 Q3 | Y1 Q4 | Y2 Q1 | Y2 Q2 | Y2 Q3 | Y2 Q4 |
|---|
| Reagents / consumables | $65,500 | $72,050 | $79,255 | $87,181 | $95,899 | $105,488 | $116,037 | $127,641 |
| Lab supplies / accessioning / packaging | $11,000 | $12,100 | $13,310 | $14,641 | $16,105 | $17,716 | $19,487 | $21,436 |
| Waste, clearinghouse, transaction fees | $4,400 | $4,840 | $5,324 | $5,856 | $6,442 | $7,086 | $7,795 | $8,574 |
| Southeast air freight | $7,800 | $8,580 | $9,438 | $10,382 | $11,420 | $12,562 | $13,818 | $15,200 |
| In-house courier | $13,750 | $15,125 | $16,638 | $18,301 | $20,131 | $22,145 | $24,359 | $26,795 |
| Staff payroll + burden | $52,608 | $52,608 | $52,608 | $52,608 | $52,608 | $52,608 | $52,608 | $52,608 |
| Facility / utilities | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 |
| Equipment lease / service contracts | $47,000 | $47,000 | $47,000 | $47,000 | $47,000 | $47,000 | $47,000 | $47,000 |
| LIMS support | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 | $6,000 |
| AI smart billing support | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 | $7,500 |
| IT / insurance / compliance / admin | $19,500 | $19,500 | $19,500 | $19,500 | $19,500 | $19,500 | $19,500 | $19,500 |
| Revenue cycle billing expense | $36,015 | $39,617 | $43,579 | $47,937 | $52,730 | $58,003 | $63,804 | $70,184 |
| Estimated monthly total | $278,574 | $292,420 | $307,652 | $324,406 | $342,836 | $363,108 | $385,408 | $409,938 |
Reagent detail by test type
| Test / code | Cost assumption | Y1 Q1 | Y1 Q2 | Y1 Q3 | Y1 Q4 | Y2 Q1 | Y2 Q2 | Y2 Q3 | Y2 Q4 |
|---|
| Tox 80307 reagents / consumables | $8 per tox screen | $8,000 | $8,800 | $9,680 | $10,648 | $11,713 | $12,884 | $14,172 | $15,590 |
| Confirmation G0483 LC-MS reagents / consumables | $35 per confirmation test | $35,000 | $38,500 | $42,350 | $46,585 | $51,244 | $56,368 | $62,005 | $68,205 |
| PGx 81418 reagents / extraction | $150 per PGx test | $15,000 | $16,500 | $18,150 | $19,965 | $21,962 | $24,158 | $26,573 | $29,231 |
| UTI PCR 0504U reagents / extraction | $75 per UTI PCR test | $7,500 | $8,250 | $9,075 | $9,983 | $10,981 | $12,079 | $13,287 | $14,615 |
Shipping and courier detail
| Line item | Assumption | Y1 Q1 | Y1 Q2 | Y1 Q3 | Y1 Q4 | Y2 Q1 | Y2 Q2 | Y2 Q3 | Y2 Q4 |
|---|
| Packaging / cold-chain supplies | $2 per total test | $4,400 | $4,840 | $5,324 | $5,856 | $6,442 | $7,086 | $7,795 | $8,574 |
| Southeast air freight / overnight specimen freight | Base $7,800/month scaled with volume | $7,800 | $8,580 | $9,438 | $10,382 | $11,420 | $12,562 | $13,818 | $15,200 |
| In-house courier routes / drivers / fuel / maintenance | Base $13,750/month scaled with volume | $13,750 | $15,125 | $16,638 | $18,301 | $20,131 | $22,145 | $24,359 | $26,795 |
Annual operating expense estimate
| Period | Operating expense estimate |
|---|
| Year 1 | $3,609,154.52 |
| Year 2 | $4,503,871.80 |
| 24 months | $8,113,026.33 |
5. Monthly gross and net profit view — Target AI model
This view uses the Target AI model collection rate of 82%. Net monthly profit is calculated as gross collections minus total operating expenses. The launch budget is shown separately at the annual and 24-month levels.
| Month | Quarter | Test volume | Gross collections | Total operating expenses | Net monthly profit before launch budget recovery | Cumulative net before launch budget recovery |
|---|
| 1 | Y1 Q1 | 2,200 | $357,363.63 | $278,573.79 | $78,789.85 | $78,789.85 |
| 2 | Y1 Q1 | 2,200 | $357,363.63 | $278,573.79 | $78,789.85 | $157,579.69 |
| 3 | Y1 Q1 | 2,200 | $357,363.63 | $278,573.79 | $78,789.85 | $236,369.54 |
| 4 | Y1 Q2 | 2,420 | $393,100.00 | $292,420.33 | $100,679.66 | $337,049.20 |
| 5 | Y1 Q2 | 2,420 | $393,100.00 | $292,420.33 | $100,679.66 | $437,728.87 |
| 6 | Y1 Q2 | 2,420 | $393,100.00 | $292,420.33 | $100,679.66 | $538,408.53 |
| 7 | Y1 Q3 | 2,662 | $432,410.00 | $307,651.53 | $124,758.46 | $663,167.00 |
| 8 | Y1 Q3 | 2,662 | $432,410.00 | $307,651.53 | $124,758.46 | $787,925.46 |
| 9 | Y1 Q3 | 2,662 | $432,410.00 | $307,651.53 | $124,758.46 | $912,683.93 |
| 10 | Y1 Q4 | 2,928.2 | $475,651.00 | $324,405.85 | $151,245.14 | $1,063,929.07 |
| 11 | Y1 Q4 | 2,928.2 | $475,651.00 | $324,405.85 | $151,245.14 | $1,215,174.21 |
| 12 | Y1 Q4 | 2,928.2 | $475,651.00 | $324,405.85 | $151,245.14 | $1,366,419.36 |
| 13 | Y2 Q1 | 3,221.0 | $523,216.10 | $342,835.61 | $180,380.49 | $1,546,799.85 |
| 14 | Y2 Q1 | 3,221.0 | $523,216.10 | $342,835.61 | $180,380.49 | $1,727,180.34 |
| 15 | Y2 Q1 | 3,221.0 | $523,216.10 | $342,835.61 | $180,380.49 | $1,907,560.83 |
| 16 | Y2 Q2 | 3,543.1 | $575,537.71 | $363,108.33 | $212,429.37 | $2,119,990.21 |
| 17 | Y2 Q2 | 3,543.1 | $575,537.71 | $363,108.33 | $212,429.37 | $2,332,419.58 |
| 18 | Y2 Q2 | 3,543.1 | $575,537.71 | $363,108.33 | $212,429.37 | $2,544,848.96 |
| 19 | Y2 Q3 | 3,897.4 | $633,091.48 | $385,408.33 | $247,683.14 | $2,792,532.10 |
| 20 | Y2 Q3 | 3,897.4 | $633,091.48 | $385,408.33 | $247,683.14 | $3,040,215.25 |
| 21 | Y2 Q3 | 3,897.4 | $633,091.48 | $385,408.33 | $247,683.14 | $3,287,898.39 |
| 22 | Y2 Q4 | 4,287.2 | $696,400.62 | $409,938.33 | $286,462.29 | $3,574,360.68 |
| 23 | Y2 Q4 | 4,287.2 | $696,400.62 | $409,938.33 | $286,462.29 | $3,860,822.98 |
| 24 | Y2 Q4 | 4,287.2 | $696,400.62 | $409,938.33 | $286,462.29 | $4,147,285.27 |
Annual and 24-month profit summary
| Period | Gross collections | Operating expenses | Net profit before launch budget recovery | Net after launch budget |
|---|
| Year 1 | $4,975,573.88 | $3,609,154.52 | $1,366,419.36 | ($23,580.64) |
| Year 2 | $7,284,737.72 | $4,503,871.80 | $2,780,865.91 | $2,780,865.91 |
| 24 months | $12,260,311.60 | $8,113,026.33 | $4,147,285.27 | $2,757,285.27 |